Functional medicine does not treat or cure MS. It investigates the nutritional, metabolic, inflammatory, and nervous system drivers that influence how the body operates in the context of MS — and builds protocols to support the body's own regulatory systems. The areas most responsive to this approach in clinical practice are fatigue, mitochondrial function, neuroinflammatory load, myelin nutrition, and nervous system regulation. This programme ran alongside the client's ongoing neurological care throughout. Conventional medicine and functional medicine are answering different questions about the same body. Both matter.

Post-vaccine neurological presentations are characterised by new or worsening neurological symptoms following vaccination — in some cases with a clear temporal relationship. Functional medicine approaches this the way it approaches any complex case: investigating immune terrain, mitochondrial function, neuroinflammatory load, spike protein status, and nervous system regulatory capacity. In this case, spike protein testing was commissioned to establish whether persistent spike protein was a contributor. It was negative. The protocol focused on terrain repair, mitochondrial rebuilding, limbic retraining, and myelin support.

Spike protein testing — in the format used here — assesses for the presence of spike protein in both circulating blood (plasma/serum) and immune cells (PBMC, peripheral blood mononuclear cells). A negative result in both compartments means spike protein was not detectable at the time of testing. This was clinically significant — it indicated that the protocol should focus on immune terrain, mitochondrial repair, and nervous system regulation rather than spike-specific interventions. Having a definitive result changed the direction of the protocol. It was worth commissioning to know.

The ketogenic diet has a body of research investigating its effects on neurological conditions including MS. Proposed mechanisms include: ketone bodies — particularly beta-hydroxybutyrate — reducing neuroinflammation by inhibiting the NLRP3 inflammasome; improved mitochondrial efficiency and ATP production in conditions where glucose metabolism is impaired; reduced circulating inflammatory cytokines; and reduced central fatigue. In this case it was combined with MCT oil, which converts rapidly to ketones and provides a direct fuel source for neurological tissue.

The limbic system regulates the body's threat-detection and stress-response systems. In post-viral, post-injury, and chronic neurological conditions, this system can become sensitised — running at a chronically elevated baseline, sustaining neuroinflammation, depleting mitochondrial resources, and blocking recovery signals. DNRS (Dynamic Neural Retraining System) and the Gupta Programme are structured neuroplasticity-based approaches that target this sensitisation directly through neuroplasticity principles. In a neurological recovery context, this is a clinical intervention targeting a specific driver — not a wellness add-on.

Uridine monophosphate (UMP) is a nucleotide and a precursor in the biosynthesis of phosphatidylcholine — a key component of myelin sheaths. In conditions involving demyelination, providing UMP alongside choline and omega-3 fatty acids (DHA) creates the nutritional environment for myelin repair and synthesis. Research, particularly from MIT, has explored the UMP-DHA-choline combination as nutritional support for synaptic membrane formation and myelin integrity. It does not directly regrow myelin — it provides the raw materials the body needs to carry out its own repair processes.

This is genuinely case-specific. This programme ran nine months and was still ongoing. The trajectory over that period was meaningful — mobility, energy, and activity levels all improving. Diet changes and foundational supplementation show effects in weeks. Mitochondrial rebuilding takes months. Myelin-related changes take the longest — the nervous system does not rebuild quickly. The client's own framing — "not out the woods yet" — captures the honest shape of complex neurological recovery. The question worth asking is not "how long?" but "am I on the right path?" — and the answer here, after nine months, appears to be yes.

Prolonged occupational chemical exposure — common in the beauty industry and similar environments — is associated in epidemiological research with increased risk of neurological conditions. Proposed mechanisms include direct neurotoxicity, disruption of the blood-brain barrier, induction of oxidative stress, and impaired liver detoxification capacity. In a neurological case with decades of such exposure, accounting for this background is clinically appropriate. A standard neurology appointment isn't structured to explore it — but it matters.